Deals
AbbVie Builds $1.4B Durham Campus, First in North Carolina
AbbVie has allocated $1.4 billion for a manufacturing campus in Durham, North Carolina, its first in the state, drawn from the company's $100 billion US…
Deals — Page 3
M&A, fundraising, IPOs, and bankruptcies in regulated industries.
Deals
Cut $1B Google Cloud Deal, Merck Targets HCP Engagement
Merck paid $1 billion to Google Cloud for access to its agentic AI platform, and the commercial team gets there first.
Deals
Buys Kashiv for $1.1B, Amneal Eyes $200B Biosimilar Market
Amneal paid $1.1 billion to buy Kashiv BioSciences: $750 million upfront in cash and equity at close, plus up to $350 million tied to pipeline milestones.
Deals
Forager Bids $1B for Repay at 75% Premium
Forager Capital Management offered $1 billion for Atlanta-based Repay Holdings at $4.80 a share, a 75% premium to the stock's 30-day volume-weighted average…
Deals
Paid $1.25B, Apollo Takes 13% of McKesson's Surgical Unit
Apollo Funds paid $1.25B for a 13% minority stake in McKesson's Medical/Surgical Solutions division, valuing MMS at roughly $13 billion.
Deals
Kelonia Sale Hands Venrock a 45-Fold Return on $20M
Venrock put $20 million into Kelonia Therapeutics.
Deals
Lilly Bets on Kelonia's In Vivo CAR-T
Lilly paid an undisclosed sum upfront for Kelonia Therapeutics on Monday, placing a large bet on in vivo CAR-T as its next platform priority.
Deals
Kailera Raises $625M in Record Biotech IPO on Nasdaq
Kailera Therapeutics raised $625 million Friday in a record-setting biotech IPO on the Nasdaq.
Deals
Kraken Paid $550M for Bitnomial's Triple CFTC License Stack
Kraken paid up to $550 million for Bitnomial, a derivatives firm, in a deal that closes by June.
Deals
UCB Paid $1.15B for Neurona's Single-Dose Epilepsy Cell Therapy
UCB paid up to $650m upfront, with up to $500m in future milestones, to buy Neurona Therapeutics in a deal valued at up to $1.15bn.
Deals
Bought Comerica. Now Fifth Third Converts 500,000 Customers by Labor Day
Fifth Third bought Comerica in February, folding in about $294 billion in assets and roughly 500,000 retail customers.
Deals
Raised $625M at $16 a Share, Kailera Tops Moderna's 2018 IPO Record
Kailera Therapeutics priced just under 40 million shares at $16 apiece Friday, pulling in $625 million on its Nasdaq debut under KLRA.
Deals
Topped $30B: Revolution Medicines Buyout Climbs on Cancer Win
Revolution Medicines had a rumored $30 billion buyout offer on the table in January.
Deals
Kailera Prices $625M IPO, Largest Biotech Since Moderna
Kailera Therapeutics priced its IPO at $625m, or $16 a share, on April 16 — at the top of its S-1 range and one of the largest biotech public offerings…
Deals
Priced at $16, Kailera Raises $625M in Largest Biotech IPO Since 2018
Kailera Therapeutics priced its IPO at $16 a share Friday, raising $625 million, the largest biotech public offering in recent memory, topping Moderna's…
Deals
Daiichi Sankyo Sold $1.55B Consumer Unit to Suntory
Daiichi Sankyo will sell its consumer health subsidiary to Suntory Holdings for 246.5 billion yen, about $1.55 billion, paid in tranches over three years.
Deals
Filed: Nir Zuk's Bid for $442M-Asset Liberty Bank
Nir Zuk, the Israeli billionaire who founded Palo Alto Networks, filed a Federal Reserve application Wednesday to acquire voting shares of DMG Bancshares…
Deals
OpenEvidence and Tandem Merge $13B in AI Into One Prescription Workflow
OpenEvidence and Tandem linked their platforms to automate the gap between clinical decisions and prior auth approvals.
deals
Deals
Cleared $22B: Q1 2026 Obesity Deals Top 2025's Full-Year Total
Biopharma committed $22 billion to obesity and diabetes licensing deals in Q1 2026, clearing last year's full-year total of $20.3 billion with three…
Deals
Aligos Sells China HBV Rights to Amoytop in $445M Deal
Aligos Therapeutics sold the Greater China rights to pevifoscorvir sodium to Fujian-based Amoytop for up to $445 million: $25 million upfront and $420…
